Department of Surgery, Yale School of Medicine, Yale University, New Haven, Connecticut.
Department of Neurology, Yale School of Medicine, Yale University, New Haven, Connecticut.
JAMA Surg. 2019 Nov 1;154(11):1055-1063. doi: 10.1001/jamasurg.2019.2952.
Thromboembolic stroke attributable to an ipsilateral carotid artery plaque is a leading cause of disability in the United States and a major source of morbidity. Randomized clinical trials have demonstrated the efficacy of carotid endarterectomy and carotid stenting at minimizing stroke risk in patients with minor stroke and transient ischemic attack. However, there is no consensus on guidelines for medical management and the timing of revascularization in patients with multiple recurrent episodes of transient ischemic attack over hours or days, an acute neurological event known as crescendo transient ischemic attack.
To review the management of and timing of intervention in patients presenting with crescendo transient ischemic attack.
This systematic review included all English-language articles published from January 1, 1985, to January 1, 2019, available from PubMed (MEDLINE) and Google Scholar. Articles were excluded if they did not include analysis of patients with symptoms, did not report the timing of intervention after crescendo transient ischemic attack, or mixed analysis of patients with stroke in evolution with patients with crescendo transient ischemic attack. The quality of the evidence was assessed with the modified rating from the Oxford Centre for Evidence-based Medicine.
Patients with crescendo transient ischemic attack were found to have a higher risk of stroke or death after carotid endarterectomy compared with patients with a single transient ischemic attack or stable stroke. With medical therapy alone, a considerable number of patients with crescendo transient ischemic attack experience a completed stroke within several months and have a poor prognosis without intervention. Urgent carotid endarterectomy, typically performed within 48 hours of initial presentation, is beneficial in carefully selected patients. There have been several reports of operative treatment within the first 24 hours of presentation; however, review of these reports does not show any additional benefit from emergency treatment. Carotid artery stenting is reserved only for selected patients with prohibitive surgical risk for endarterectomy. The literature does not clearly support any additional benefit of intravenous heparin therapy over mono or dual antiplatelet therapy prior to carotid endarterectomy.
Crescendo transient ischemic attack is best managed with optimal medical management as well as urgent carotid endarterectomy within 2 days of presentation. Surgical endarterectomy appears to be preferred because of the increased embolic potential of bifurcation plaque, whereas stenting is an option for patients with contraindications for surgery. With ongoing advances in cerebrovascular imaging and medical treatment of stroke, there is a need for better evidence to determine the optimal timing and preoperative medical management of patients with crescendo transient ischemic attack.
由同侧颈动脉斑块引起的血栓栓塞性中风是美国残疾的主要原因,也是发病率的主要来源。随机临床试验已经证明了颈动脉内膜切除术和颈动脉支架置入术在减少小中风和短暂性脑缺血发作患者中风风险方面的有效性。然而,对于在数小时或数天内反复发作短暂性脑缺血发作的患者,即称为渐强短暂性脑缺血发作的急性神经事件,对于这些患者的医学管理和血运重建时机,尚无共识。
回顾渐强短暂性脑缺血发作患者的治疗和干预时机。
本系统综述纳入了 1985 年 1 月 1 日至 2019 年 1 月 1 日期间发表的所有英文文章,来自 PubMed(MEDLINE)和谷歌学术。如果文章未分析有症状的患者、未报告渐强短暂性脑缺血发作后干预的时间,或混合分析进展性中风与渐强短暂性脑缺血发作患者,这些文章将被排除。使用牛津循证医学中心的改良评级评估证据质量。
与单发短暂性脑缺血发作或稳定中风患者相比,渐强短暂性脑缺血发作患者颈动脉内膜切除术后中风或死亡风险更高。单独采用药物治疗,相当数量的渐强短暂性脑缺血发作患者在数月内发生完全性中风,如果不进行干预,预后不良。紧急颈动脉内膜切除术通常在初始发作后 48 小时内进行,对精心挑选的患者有益。有几例报告在发作后 24 小时内进行手术治疗;然而,对这些报告的回顾并没有显示出紧急治疗的任何额外益处。颈动脉支架置入术仅保留给有手术禁忌的颈动脉内膜切除术的选择性患者。文献并未明确支持在颈动脉内膜切除术前静脉内肝素治疗优于单药或双联抗血小板治疗。
渐强短暂性脑缺血发作的最佳治疗方法是采用最佳药物治疗,并在发病后 2 天内进行紧急颈动脉内膜切除术。由于分叉斑块的栓塞潜力增加,手术内膜切除术似乎是首选,而支架置入术是手术禁忌患者的一种选择。随着脑血管成像和中风治疗的不断进步,需要更好的证据来确定渐强短暂性脑缺血发作患者的最佳时机和术前药物管理。